Saladax Biomedical Appoints Stacie Geffner-Atiya
Saladax Biomedical, Inc., known for its groundbreaking solutions in therapeutic drug monitoring, is excited to share that Ms. Stacie Geffner-Atiya has joined the company as the Director of Regulatory and Quality. With a solid background spanning over 20 years in regulatory affairs, particularly in the diagnostics and medical device sectors, Ms. Geffner-Atiya is well-equipped to steer the regulatory landscape of innovative practices.
Expertise in Navigating Regulatory Challenges
Throughout her career, Ms. Geffner-Atiya has demonstrated exceptional skill in crafting regulatory strategies for both established corporations and dynamic start-ups. Her work has included securing essential clearances and approvals like IVDR, 510(k) submissions, and PMAs. This profound knowledge uniquely positions her to lead Saladax Biomedical in the complex world of global regulations.
A Proven Track Record
Ms. Geffner-Atiya's experience encompasses a wide range of medical technologies, including point-of-care glucose meters, endoscopes, infusion pumps, and insulin delivery systems. Her successful endeavors indicate her ability to adeptly handle various regulatory requirements and compliance issues, ensuring that Saladax’s products meet the stringent standards necessary for market entry.
Leadership Insights on Her Appointment
Expressing enthusiasm about Ms. Geffner-Atiya’s addition to the team, Sal Salamone, CEO of Saladax Biomedical, Inc., remarked on the value of her expertise. "We are thrilled to welcome Ms. Geffner-Atiya to the Saladax team. Her broad regulatory expertise and strategic leadership will be instrumental as we continue to expand our portfolio of rapid and precise therapeutic drug monitoring assays. Her proven success in securing regulatory approvals will ensure that our innovative solutions reach more patients and healthcare providers worldwide," said Salamone.
Educational Background and Vision
Ms. Geffner-Atiya earned her Bachelor of Science degree from the State University of New York at Brockport. Her foundational education supports her extensive regulatory expertise, which will be pivotal in overseeing compliance, quality assurance, and submission strategies at Saladax. This role enhances Saladax’s ongoing commitment to providing high-quality diagnostic solutions that improve patient outcomes.
About Saladax Biomedical, Inc.
Saladax Biomedical, Inc., headquartered in Bethlehem, is a leading private enterprise focused on developing, manufacturing, and marketing assays that deliver rapid assessments of therapeutic drug levels. These innovations are particularly vital for essential medications prescribed by healthcare professionals specializing in psychiatry and oncology. Saladax’s proprietary technology has been pivotal in clinical settings since its inception in 2007, allowing clinicians to optimize patient care effectively.
Collaboration with Pharmaceutical Companies
The company also engages with prominent pharmaceutical partners to create tests that support clinical trials and companion diagnostics. This collaborative approach ensures that Saladax remains at the forefront of advancements in therapeutic monitoring, aiming to benefit patients and healthcare providers alike.
Frequently Asked Questions
What is the primary focus of Saladax Biomedical, Inc.?
Saladax Biomedical focuses on developing innovative therapeutic drug monitoring solutions to improve patient care in psychiatry and oncology.
Who is Ms. Stacie Geffner-Atiya?
Ms. Stacie Geffner-Atiya is the newly appointed Director of Regulatory and Quality at Saladax Biomedical, bringing over 20 years of regulatory experience.
What will Ms. Geffner-Atiya oversee in her new role?
She will oversee regulatory compliance, quality assurance, and global submission strategies to enhance Saladax's diagnostic solutions.
How does Saladax Biomedical support clinical trials?
Saladax collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics.
When was Saladax Biomedical founded?
Saladax Biomedical was founded in 2007 and has been a pioneer in rapid therapeutic drug monitoring technology since then.
